vs
Side-by-side financial comparison of Dominari Holdings Inc. (DOMH) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Dominari Holdings Inc. is the larger business by last-quarter revenue ($30.1M vs $23.0M, roughly 1.3× Intellia Therapeutics, Inc.). Intellia Therapeutics, Inc. runs the higher net margin — -416.2% vs -438.1%, a 22.0% gap on every dollar of revenue. On growth, Dominari Holdings Inc. posted the faster year-over-year revenue change (220.4% vs 78.8%). Over the past eight quarters, Dominari Holdings Inc.'s revenue compounded faster (369.1% CAGR vs -10.8%).
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
DOMH vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.1M | $23.0M |
| Net Profit | $-131.8M | $-95.8M |
| Gross Margin | — | — |
| Operating Margin | -8.9% | -428.9% |
| Net Margin | -438.1% | -416.2% |
| Revenue YoY | 220.4% | 78.8% |
| Net Profit YoY | -12426.2% | 25.7% |
| EPS (diluted) | $-6.94 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.1M | $23.0M | ||
| Q3 25 | $50.8M | $13.8M | ||
| Q2 25 | $34.1M | $14.2M | ||
| Q1 25 | $8.1M | $16.6M | ||
| Q4 24 | $9.4M | $12.9M | ||
| Q3 24 | $4.0M | $9.1M | ||
| Q2 24 | $6.2M | $7.0M | ||
| Q1 24 | $1.4M | $28.9M |
| Q4 25 | $-131.8M | $-95.8M | ||
| Q3 25 | $125.2M | $-101.3M | ||
| Q2 25 | $16.6M | $-101.3M | ||
| Q1 25 | $-32.5M | $-114.3M | ||
| Q4 24 | $1.1M | $-128.9M | ||
| Q3 24 | $-4.2M | $-135.7M | ||
| Q2 24 | $-6.1M | $-147.0M | ||
| Q1 24 | $-5.4M | $-107.4M |
| Q4 25 | -8.9% | -428.9% | ||
| Q3 25 | -3.1% | -808.9% | ||
| Q2 25 | -57.0% | -772.2% | ||
| Q1 25 | -394.6% | -726.6% | ||
| Q4 24 | 0.4% | -1059.9% | ||
| Q3 24 | -79.1% | -1589.0% | ||
| Q2 24 | -44.3% | -1998.6% | ||
| Q1 24 | -205.2% | -394.0% |
| Q4 25 | -438.1% | -416.2% | ||
| Q3 25 | 246.4% | -735.2% | ||
| Q2 25 | 48.7% | -710.8% | ||
| Q1 25 | -400.5% | -687.6% | ||
| Q4 24 | 11.4% | -1001.2% | ||
| Q3 24 | -104.2% | -1489.5% | ||
| Q2 24 | -99.1% | -2112.6% | ||
| Q1 24 | -398.0% | -371.3% |
| Q4 25 | $-6.94 | $-0.81 | ||
| Q3 25 | $7.27 | $-0.92 | ||
| Q2 25 | $1.12 | $-0.98 | ||
| Q1 25 | $-3.02 | $-1.10 | ||
| Q4 24 | $0.21 | $-1.27 | ||
| Q3 24 | $-0.67 | $-1.34 | ||
| Q2 24 | $-1.01 | $-1.52 | ||
| Q1 24 | $-0.91 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.5M | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $69.4M | $671.4M |
| Total Assets | $112.9M | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.5M | $449.9M | ||
| Q3 25 | $176.2M | $511.0M | ||
| Q2 25 | $28.2M | $459.7M | ||
| Q1 25 | $18.9M | $503.7M | ||
| Q4 24 | $8.2M | $601.5M | ||
| Q3 24 | $7.2M | $658.1M | ||
| Q2 24 | $12.1M | $691.1M | ||
| Q1 24 | $7.1M | $791.3M |
| Q4 25 | $69.4M | $671.4M | ||
| Q3 25 | $210.2M | $748.4M | ||
| Q2 25 | $88.6M | $715.3M | ||
| Q1 25 | $42.4M | $779.9M | ||
| Q4 24 | $39.9M | $872.0M | ||
| Q3 24 | $38.3M | $962.6M | ||
| Q2 24 | $42.4M | $971.1M | ||
| Q1 24 | $47.7M | $1.0B |
| Q4 25 | $112.9M | $842.1M | ||
| Q3 25 | $223.4M | $925.3M | ||
| Q2 25 | $109.3M | $898.9M | ||
| Q1 25 | $52.3M | $986.2M | ||
| Q4 24 | $47.1M | $1.2B | ||
| Q3 24 | $43.4M | $1.2B | ||
| Q2 24 | $49.1M | $1.2B | ||
| Q1 24 | $52.2M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $22.7M | $-69.3M |
| Free Cash FlowOCF − Capex | — | $-69.4M |
| FCF MarginFCF / Revenue | — | -301.6% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.7M | $-69.3M | ||
| Q3 25 | $-4.9M | $-76.9M | ||
| Q2 25 | $-353.0K | $-99.6M | ||
| Q1 25 | $1.2M | $-148.9M | ||
| Q4 24 | $-16.7M | $-85.2M | ||
| Q3 24 | $-4.7M | $-84.8M | ||
| Q2 24 | $1.4M | $-58.2M | ||
| Q1 24 | $-8.6M | $-120.7M |
| Q4 25 | — | $-69.4M | ||
| Q3 25 | — | $-76.9M | ||
| Q2 25 | — | $-99.9M | ||
| Q1 25 | — | $-149.7M | ||
| Q4 24 | — | $-86.2M | ||
| Q3 24 | — | $-86.1M | ||
| Q2 24 | — | $-59.2M | ||
| Q1 24 | — | $-123.2M |
| Q4 25 | — | -301.6% | ||
| Q3 25 | — | -558.2% | ||
| Q2 25 | — | -701.0% | ||
| Q1 25 | — | -900.1% | ||
| Q4 24 | — | -669.4% | ||
| Q3 24 | — | -945.2% | ||
| Q2 24 | — | -850.9% | ||
| Q1 24 | — | -425.7% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 4.4% | ||
| Q4 24 | — | 7.6% | ||
| Q3 24 | — | 14.0% | ||
| Q2 24 | — | 14.5% | ||
| Q1 24 | — | 8.7% |
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
